Straits Times Index
3,072.91 -11.79 (-0.38%) Nikkei
33,486.89 +165.67 (+0.50%) Hang Seng
17,034.24 +40.80 (+0.24%) FTSE 100
7,423.46 -31.78 (-0.43%) Bitcoin USD
37,810.22 -340.10 (-0.89%) CMC Crypto 200
781.05 -4.45 (-0.57%)
Agios Pharmaceuticals, Inc. (AGIO)
After hours:
- Zacks
Agios (AGIO) Meets Clinical Proof-of-Concept in Anemia Treatment
Data from a phase IIa study shows that 40% of patients with low transfusion burden who received Agios' (AGIO) investigational PK activator drug met the transfusion independence endpoint.
- GlobeNewswire
Agios Announces Clinical Proof-of-Concept in Phase 2a Trial of AG-946 for the Treatment of Anemia in Lower-Risk Myelodysplastic Syndromes
– 40 Percent of Low Transfusion Burden Cohort Achieved Transfusion Independence;One Study Patient Achieved Hemoglobin Response Endpoint – – Safety Profile Consistent with Data Reported in Healthy Volunteers Study – – Company Expects to Initiate Phase 2b Study in Mid-2024 – CAMBRIDGE, Mass., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, today announced that clinical proof-of-concep
- Insider Monkey
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q3 2023 Earnings Call Transcript
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q3 2023 Earnings Call Transcript November 2, 2023 Agios Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-1.64, expectations were $-1.69. Operator: Good day and thank you for standing by. Welcome to the Agios Pharmaceuticals Incorporated quarter three 2023 earnings conference call. At this time, all participants are in a listen-only […]
